Compare · GILD vs REPL
GILD vs REPL
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Replimune Group Inc. (REPL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and REPL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $160.36B, about 205.1x REPL ($782.0M).
- Over the past year, GILD is up 13.4% and REPL is down 11.6% - GILD leads by 25.0 points.
- GILD has been more active in the news (19 items in the past 4 weeks vs 13 for REPL).
- Both have 25 recent analyst ratings on file.
- Company
- Gilead Sciences Inc.
- Replimune Group Inc.
- Price
- $128.17-0.64%
- $8.99-5.07%
- Market cap
- $160.36B
- $782.0M
- 1M return
- -4.49%
- +169.57%
- 1Y return
- +13.44%
- -11.60%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2018
- News (4w)
- 19
- 13
- Recent ratings
- 25
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Replimune Group Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Latest GILD
- Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
- GILEAD SCIENCES AND LAKEFRONT COMPLETE ACQUISITION OF OURO MEDICINES TO FURTHER EXPAND INFLAMMATION PIPELINE
- Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
- Chairman & CEO O'Day Daniel Patrick sold $1,971,847 worth of shares (15,000 units at $131.46) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 617,567 units (SEC Form 4)
- Gilead's Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead's Livdelzi (Seladelpar)
- FDA Approval for HEPCLUDEX issued to GILEAD SCIENCES INC
- FDA Grants Accelerated Approval to Gilead's Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors
- New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Latest REPL
- Chief Commercial Officer Sarchi Christopher sold $110,880 worth of shares (12,000 units at $9.24) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 180,962 units (SEC Form 4)
- Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
- Replimune upgraded by Analyst with a new price target
- Replimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
- SEC Form SCHEDULE 13G filed by Replimune Group Inc.
- Chief Medical Officer Xynos Konstantinos sold $71,237 worth of shares (14,023 units at $5.08), decreasing direct ownership by 6% to 235,662 units (SEC Form 4) to satisfy tax liability
- Chief Accounting Officer Schwendenman Andrew sold $40,102 worth of shares (7,894 units at $5.08), decreasing direct ownership by 7% to 107,057 units (SEC Form 4) to cover taxes
- Chief Commercial Officer Sarchi Christopher sold $43,820 worth of shares (8,626 units at $5.08), decreasing direct ownership by 4% to 192,962 units (SEC Form 4) (for tax liability)